[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334149-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334149-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","mutagenic-impact-and-evolutionary-influence-of-radiotherapy-in-hematologic-malignancies","Mutagenic Impact and Evolutionary Influence of Radiotherapy in Hematologic Malignancies","","Ionizing radiotherapy is widely used for palliative and curative management of hematologic malignancies, yet the magnitude of RT-induced DNA damage and how it shapes tumor evolution and interactions with chemotherapy remains insufficiently characterized. Using whole genome sequencing from patients with large B-cell lymphoma, multiple myeloma, and myeloid neoplasms, the study identifies the ID8 mutational signature specifically in relapsed disease. Exposure to both RT and mutagenic chemotherapy produces ID8, and single-cell colony sequencing reveals a dose-response relationship between RT and platinum-related ID8 formation. Using ID8 as a genomic barcode, the work supports the concept that a single RT-resistant cell can seed systemic relapse.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/mutagenic-impact-and-evolutionary-influence-of-radiotherapy-in-hematologic-malignancies/334149/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/mutagenic-impact-and-evolutionary-influence-of-radiotherapy-in-hematologic-malignancies/334149.png","ImageObject",300,407,{"name":42,"@type":43},"Quinn","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main goal regarding radiotherapy in hematologic malignancies?","Question",{"text":63,"@type":64},"To determine the extent of RT-induced DNA damage in hematologic cancers and how it influences evolutionary trajectories and relapse, including interaction with chemotherapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the impact of radiotherapy studied in this work?",{"text":68,"@type":64},"The study used whole genome sequencing from patient samples and single-cell colonies derived from treated lymphoma cells to examine mutational signatures and dose-response effects.",{"name":70,"@type":61,"acceptedAnswer":71},"What role does the ID8 mutational signature play in the findings?",{"text":72,"@type":64},"ID8 was identified only in relapsed disease and was detected after combined exposure to RT and mutagenic chemotherapy, serving as a genomic barcode for relapse origin.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334149,1790757657,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":99,"preview_page_count":4},962075114765,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","bioRxiv preprint doi: [https://doi.org/10.1101/2024.11.15.623836](https://doi.org/10.1101/2024.11.15.623836); this version posted November 18, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made  \navailable under aCC-BY-ND 4.0 International license.  \nMutagenic impact and evolutionary influence of radiotherapy in hematologic malignancies  \nBenjamin Diamond1*, Dhanvantri Chahar2*, Michael D. Jain3*, Alexandra M. Poos4,5*, Michael Durante1 , Bachisio Ziccheddu 1 , Marcella Kaddoura 1 , Marios Papadimitriou1 , Kylee Maclachlan6 , Tomas Jelinek7 , Faith Davies8 , Nicholas B Figura9 , Gareth Morgan8 , Elias Mai4 , Katja C. Weisel 10 , Roland Fenk11 , Marc S. Raab4,5 , Saad Usmani6 , Ola Landgren 1 , Frederick L. Locke3 , Hartmut Goldschmidt4 , Jonathan H. Schatz2\\# , Niels Weinhold4,5\\# , Francesco Maura1\\#  \n1 Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA  \n2 Lymphoma Service, Sylvester Comprehensive Cancer Center, Miami, FL, USA.  \n3 Lymphoma Service, Moffitt Cancer Center, Tampa, FL, USA.  \n4 Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany.  \n5 Clinical Cooperation Unit Molecular Hematology/Oncology, Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg University, and German Cancer Research Center (DKFZ), Heidelberg, Germany.  \n6 Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.  \n7 Department of Hemato-Oncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Czech Republic.  \n8 Myeloma Research Program, NYU Langone, Perlmutter Cancer Center, New York, NY, USA.  \n9 Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL, USA.  \n10 Department of Oncology, Hematology and Blood and Marrow Transplant, University Medical Center Hamburg-Eppendorf, Hamburg, Germany  \n11 Department of Hematology, Oncology and Clinical Immunology, University-Hospital Duesseldorf, Duesseldorf, Germany  \nCorresponding Authors  \nFrancesco Maura, MD  \nMyeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, 1120 NW 14th Street, Clinical Research Building  \nMiami, FL 33136 Phone (305) 243-7687  \nE-mail: [fxm557@med.miami.edu](fxm557@med.miami.edu)  \nNiels Weinhold, PhD  \nHeidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany.  \nE-mail: niels.weinhold@med. uni-heidelberg.de  \nKey Words: Whole Genome Sequencing, Mutational Signatures, Radiation, Radiotherapy, DNA damage, Multiple Myeloma, Diffuse Large B-cell Lymphoma  \nShort Title: Mutagenic Impact of Radiotherapy in Hematologic Malignancy  \nbioRxiv preprint doi: [https://doi.org/10.1101/2024.11.15.623836](https://doi.org/10.1101/2024.11.15.623836); this version posted November 18, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made  \navailable under aCC-BY-ND 4.0 International license.  \nABSTRACT  \nIonizing radiotherapy (RT) is a widely used palliative and curative treatment strategy for malignancies. In solid tumors, RT-induced double strand breaks lead to the accumulation ofindels, and their repair by non-homologous end-joining has been linked to the ID8 mutational signature in resistant cells. However, the extent of RT-induced DNA damage in hematologic malignancies and its impact on their evolution and interplay with commonly used chemotherapies has not yet been explored. Here, we interrogated 580 whole genome sequencing (WGS) from patients with large B-cell lymphoma, multiple myeloma, and myeloid neoplasms and identified ID8 only in relapsed disease. Yet, it was detected ","cbCaihtBSc0c4C0r","https://ap.wps.com/l/cbCaihtBSc0c4C0r","pdf",5368199,24,"English","# Abstract\n# Introduction\n## Radiotherapy in hematologic malignancies\n## DNA double-strand breaks and mutational signatures\n## Evidence gaps at relapse\n# Methods and Data (implied)\n## Whole genome sequencing cohort\n## Single-cell colony experiments\n# Results (implied)\n## ID8 signature detection in relapse\n## Dose-response between RT and platinum\n## Genomic barcode and relapse seeding","[{\"question\":\"What is the main goal regarding radiotherapy in hematologic malignancies?\",\"answer\":\"To determine the extent of RT-induced DNA damage in hematologic cancers and how it influences evolutionary trajectories and relapse, including interaction with chemotherapy.\"},{\"question\":\"How was the impact of radiotherapy studied in this work?\",\"answer\":\"The study used whole genome sequencing from patient samples and single-cell colonies derived from treated lymphoma cells to examine mutational signatures and dose-response effects.\"},{\"question\":\"What role does the ID8 mutational signature play in the findings?\",\"answer\":\"ID8 was identified only in relapsed disease and was detected after combined exposure to RT and mutagenic chemotherapy, serving as a genomic barcode for relapse origin.\"}]","Mutagenic Impact and Evolutionary Influence of Radiotherapy in Hematologic Malignancies | PDF",1790005513]